@article{d47e597d8f0347249e969a45b9f2d8de,
title = "White matter integrity in dementia with Lewy bodies: A voxel-based analysis of diffusion tensor imaging",
abstract = "Many patients with dementia with Lewy bodies (DLB) have overlapping Alzheimer's disease (AD)-related pathology, which may contribute to white matter (WM) diffusivity alterations on diffusion tensor imaging (DTI). Consecutive patients with DLB (n= 30), age- and sex-matched AD patients (n= 30), and cognitively normal controls (n= 60) were recruited. All subjects underwent DTI, 18F 2-fluoro-deoxy-d-glucose, and 11CPittsburgh compound B positron emission tomography scans. DLB patients had reduced fractionalanisotropy (FA) in the parietooccipital WM but not elsewhere compared with cognitively normal controls, and elevated FA in parahippocampal WM compared with AD patients, which persisted after controlling for β-amyloid load in DLB. The pattern of WM FA alterations on DTI was consistent with the more diffuse posterior parietal and occipital glucose hypometabolism of 2-fluoro-deoxy-d-glucose positron emission tomography in the cortex. DLB is characterized by a loss of parietooccipital WM integrity, independent of concomitant AD-related β-amyloid load. Cortical glucose hypometabolism accompanies WM FA alterations with a concordant pattern of gray and WM involvement in the parietooccipital lobes in DLB.",
keywords = "Amyloid-beta load, Cortical hypometabolism, Dementia with Lewy bodies, Diffusion tensor imaging, Voxel-based analysis, White matter integrity",
author = "Zuzana Nedelska and Schwarz, {Christopher G.} and Boeve, {Bradley F.} and Lowe, {Val J.} and Reid, {Robert I.} and Przybelski, {Scott A.} and Lesnick, {Timothy G.} and Gunter, {Jeffrey L.} and Senjem, {Matthew L.} and Ferman, {Tanis J.} and Smith, {Glenn E.} and Geda, {Yonas E.} and Knopman, {David S.} and Petersen, {Ronald C.} and Jack, {Clifford R.} and Kejal Kantarci",
note = "Funding Information: Yonas E. Geda is in part supported by AG-16574, Edli Foundation , RWJ Foundation and European Regional Development Fund-Project FNUSA-ICRC (CZ.1.05/1.1.00/02.0123). Zuzana Nedelska is supported by CTSA Grant Number UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH; Grant Agency of Charles University in Prague (doctoral student grant 624012); by European Regional Development Fund—Project FNUSA-ICRC (CZ.1.05/1.1.00/02.0123), European Social Fund (CZ.1.07/2.3.00/20.0117), and the State Budget of the Czech Republic. Funding Information: Funding: Financial support for the conduct of the research was provided by the NIH ( R01 AG040042 , P50 AG016574 , U01 AG06786 , R01 AG11378 , C06 RR018898 ), the Mangurian Foundation , and the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer s Disease Research Program. Sponsors did not have any role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. Funding Information: Z. Nedelska, C. Schwarz, R. Reid, S. Przybelski, T. Lesnick, J. Gunter, and M. Senjem report no disclosures. B. Boeve has served as an investigator for a clinical trial sponsored by Cephalon, Inc. He has received honoraria from the American Academy of Neurology. He receives research support from the National Institute on Aging ( P50-AG16574 [Co-I], U01 AG06786 [Co-I], R01-AG15866 [Co-I], and U24-AG26395 [Co-I]), and the Alzheimer's Association ( IIRG-05–14,560 [PI]).T. Ferman is funded by the NIH (Mayo Clinic Alzheimer's Disease Research Center/Project 1-P50-AG16574/P1 [Co-I]). G. Smith is funded by the NIH ( P50-AG16574 ). D. Knopman serves as Deputy Editor for Neurology; serves on a Data Safety Monitoring Board for Lundbeck Pharmaceuticals and for the Dominantly Inherited Alzheimer's Disease Treatment Unit. He is participating in clinical trials sponsored by Lilly Pharmaceuticals and TauRx Pharmaceuticals. He receives research support from the NIH . R. Petersen serves on scientific advisory boards for Elan Pharmaceuticals, Wyeth Pharmaceuticals, and GE Healthcare and receives research support from the NIH ( P50-AG16574 [PI] and U01-AG06786 [PI], R01-AG11378 [Co-I], and U01–24904 [Co-I]). C. Jack serves as a consultant for Janssen, Bristol-Meyer-Squibb, General Electric, Siemens, and Johnson and Johnson and is involved in clinical trials sponsored by Allon and Baxter, Inc. He receives research funding from the National Institutes of Health ( R01-AG011378 , RO1-AG037551 , U01-HL096917 , U01-AG032438 , U01-AG024904 ), and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation Family. K. Kantarci serves on the data safety monitoring board for Pfizer Inc and Takeda Global Research & Development Center, Inc; and she is funded by the NIH ( R01AG040042 [PI], P50 AG44170 /Project 2 [PI], P50 AG16574 /Project 1 [PI], R01 AG11378 [Co-I], U19 AG10483 [Co-I], U01 AG042791 [Co-I]), and Minnesota Partnership for Biotechnology and Medical Genomics ( PO03590201 [PI]). Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",
year = "2015",
month = jun,
day = "1",
doi = "10.1016/j.neurobiolaging.2015.03.007",
language = "English (US)",
volume = "36",
pages = "2010--2017",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "6",
}